Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 15/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.41 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3954594 | 1.00 | SLC6A2 (0.54) | SLC6A2SLC6A4GPR139CHRM2CHRM1 | |
| SCHEMBL3952070 | 0.96 | SLC6A2 (0.50) | SLC6A2GPR139 | |
| SCHEMBL4643691 | 0.86 | SLC6A2 (0.53) | SLC6A2SLC6A4CHRM2CHRM1CHRM3 | |
| SCHEMBL27656001 | 0.84 | SLC6A2 (0.52) | SLC6A2SLC6A4 | |
| SCHEMBL5717985 | 0.84 | SLC6A2 (0.52) | SLC6A2SLC6A4 | |
| SCHEMBL28763192 | 0.84 | SLC6A2 (0.52) | SLC6A2SLC6A4 | |
| SCHEMBL3953696 | 0.84 | SLC6A2 (0.51) | SLC6A2SLC6A4CHRM2CHRM1CHRM3 | |
| SCHEMBL4050433 | 0.83 | PTGS1 (0.54) | SLC6A2SLC6A4CHRM2CHRM1CHRM3 | |
| SCHEMBL3954807 | 0.82 | FFAR1 (0.44) | SLC6A2GPR139 | |
| SCHEMBL3953135 | 0.81 | SLC6A2 (0.46) | SLC6A2GPR139 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1957470-A1 | PROCESS FOR SELECTIVE SYNTHESIS OF ENANTIOMERS OF SUBSTITUTED 1-(2-AMINO-1-PHENYL-ETHYL)-CYCLOHEXANOLS | Wyeth (US) | 2008-08-20 | — | — | EP | claimed |
| US-20070135449-A1 | Process for selective synthesis of enantiomers of substituted 1-(2-amino-1-phenyl-ethyl)-cyclohexanols | WYETH (US) | 2007-06-14 | — | — | US | claimed |
| WO-2007067501-A1 | PROCESS FOR SELECTIVE SYNTHESIS OF ENANTIOMERS OF SUBSTITUTED 1-(2-AMINO-1-PHENYL-ETHYL)-CYCLOHEXANOLS | WYETH (US) | 2007-06-14 | — | — | WO | claimed |
| US-7612210-B2 | Process for selective synthesis of enantiomers of substituted 1-(2-amino-1-phenyl-ethyl)-cyclohexanols | WYETH (US) | 2009-11-03 | — | — | US | disclosed |
| US-7612210-B2 | Process for selective synthesis of enantiomers of substituted 1-(2-amino-1-phenyl-ethyl)-cyclohexanols | WYETH (US) | 2009-11-03 | — | — | US | disclosed |
| US-7612210-B2 | Process for selective synthesis of enantiomers of substituted 1-(2-amino-1-phenyl-ethyl)-cyclohexanols | WYETH (US) | 2009-11-03 | — | — | US | disclosed |
| US-20090227585-A1 | SUBSTITUTED N-HETEROCYCLE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2009-09-10 | — | — | US | disclosed |
| US-7550485-B2 | Substituted N-heterocycle derivatives and methods of their use | WYETH (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550456-B2 | Substituted aryl cycloalkanoyl derivatives and methods of their use | WYETH (US) | 2009-06-23 | — | — | US | disclosed |
| US-7524846-B2 | Arylalkyl- and cycloalkylalkyl-piperazine derivatives and methods of their use | WYETH (US) | 2009-04-28 | — | — | US | disclosed |
| US-7491723-B2 | Alkanol and cycloalkanol-amine derivatives and methods of their use | WYETH (US) | 2009-02-17 | — | — | US | disclosed |
| US-20050187251-A1 | Substituted N-heterocycle derivatives and methods of their use | WYETH (US) | 2005-08-25 | — | — | US | disclosed |
| US-20050171115-A1 | Alkanol and cycloalkanol-amine derivatives and methods of their use | WYETH (US) | 2005-08-04 | — | — | US | disclosed |
| US-20050148595-A1 | Arylalkyl-and cycloalkylalkyl-piperazine derivatives and methods of their use | WYETH (US) | 2005-07-07 | — | — | US | disclosed |
| US-20050143579-A1 | Substituted aryl cycloalkanol derivatives and methods of their use | WYETH (US) | 2005-06-30 | — | — | US | disclosed |
| WO-2005037207-A2 | ARYLALKYL-PIPERAZINE DERIVATIVES FOR THE TREATMENT OF CONDITIONS AMELIORATED BY MONOAMINE REUPTAKE INCLUDING VASOMOTOR SYMPTOMS (VMS) | WYETH (US) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005037807-A1 | ARYLALKYL- AND CYCLOALKYLALKYL-PIPERAZINE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005037809-A1 | SUBSTITUTED ARYL CYCLOALKANOL DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005037279-A1 | 1- 2’ (1, 4’-BIPERIDIN-1’-YL)-1- (PHENYL) -ETHYL CYCLOHEXANOL DERIVATIVES AS MONOAMINE REUPTAKE MODULATORS FOR THE TREATMENT OF VISOMOTOR SYMPTOMS | WYETH (US) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005037283-A1 | FUSED-ARYL AND HETEROARYL DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143579-A1 | Substituted aryl cycloalkanol derivatives and methods of their use | HTR3A, MAOA, FAAH | SLC6A2 125/4885SLC6A4 72/4885GPR139 848/4885 |
| US-20050148595-A1 | Arylalkyl-and cycloalkylalkyl-piperazine derivatives and methods of their use | GLS, HTR5A, HTR3A | SLC6A2 108/4885SLC6A4 31/4885GPR139 803/4885 |
| US-20050171115-A1 | Alkanol and cycloalkanol-amine derivatives and methods of their use | FAAH, HTR3A, MAOA | SLC6A2 115/4885SLC6A4 82/4885GPR139 674/4885 |
| US-20090227585-A1 | SUBSTITUTED N-HETEROCYCLE DERIVATIVES AND METHODS OF THEIR USE | MAOA, MAOB, SDHA | SLC6A2 71/4885SLC6A4 44/4885GPR139 1754/4885 |
| US-20050187251-A1 | Substituted N-heterocycle derivatives and methods of their use | MAOA, MAOB, SDHA | SLC6A2 71/4885SLC6A4 44/4885GPR139 1754/4885 |
| US-20070135449-A1 | Process for selective synthesis of enantiomers of substituted 1-(2-amino-1-phenyl-ethyl)-cyclohexanols | MAP2K4, MAP2K1, MAP2K6 | SLC6A2 3642/4885SLC6A4 3291/4885GPR139 4484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.